1994-2020. All Rights Reserved. Online Journal of Veterinary Research. You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to OJVR publications. This article may be copied once but may not be, reproduced or re-transmitted without the express permission of the editors.


OJVRTM

Online Journal of Veterinary Research

(Including Medical and Laboratory Research)

Established 1994

ISSN 1328-925X

 

Volume 22 (11):1068-1076, 2018.


Effect of sirolimus and doxorubicin on aberrant colorectal crypt foci induced by azoxymethane in Balb/C male mice.

 

Eman S Hameed and Falah Muosa Kadhim AL-Rekabi

 

College of Veterinary Medicine, University of Baghdad.

 

ABSTRACT

 

Hameed ES, Kadhim AL-Rekabi FM., Effect of sirolimus and doxorubicin on aberrant colorectal crypt foci induced by azoxymethane in Balb/C male mice, Onl J Vet Res., 22 (11):1068-1076, 2018. Authors report effect of sirolimus and doxorubicin on aberrant crypt foci induced with azoxymethane (AOM) in Balb/C male mice. Aberrant colorectal crypt foci stem cells in 30 mice were induced by intraperitoneal (IP) administration of 10mg/kg Azoxymethane IP once weekly for 2 weeks. Groups of 10 mice each were then gavaged daily 34g/kg sirolimus (Group 1) for 4 weeks or 50mg/m Doxorubicin (Group 2) once weekly (after azoxymethane treatments), for 4 weeks. Cancer controls (Group 3) consisted of 10 mice given only AOM as described. Non-cancer controls (Group 4) were injected 2 ml saline IP daily for 4 weeks. Mice were sacrificed for tissue samples at day 28. Aberrant crypt foci (ACF) were counted by methylene blue and proliferation cell nuclear antigen (PCNA) by immunochemistry and scored as low 0-4 and high levels of expression ˃ 4-12. Compared with cancer controls (9.66 1.20A), we found significant declines in ACF in mice given Sirolimus 2.66 + 0.33 or rapamycin 1.66 + 0.33, and PCNA (12 in cancer controls and 0.8 in treated mice). However we found no difference between treatments.

 

Key words: Sirolimus, Doxorubicin, Aberrant crypt foci, mice. Raw data provided.Key words: Sirolimus, Doxorubicin, Aberrant crypt foci, mice. Raw data provided.


MAIN

 

FULL-TEXT (SUBSCRIBE OR PURCHASE TITLE)